Apyx Medical Q1 revenue up 45% to $12.5M, net loss widens, guidance narrowed

Apyx Medical Corp

2022-Q1 EPS reported -$0.17 revenue$12,493,000

Revenue $12.5M (+45% YoY); Advanced Energy $10.8M (+41%), OEM $1.7M (+72%).
Net loss attributable to stockholders $5.9M ($0.17/share) vs $4.9M ($0.14) prior year.
Adjusted EBITDA loss $4.0M vs $3.4M; operating expenses rose 33% to $14.1M.
FY2022 revenue guidance narrowed to $52.5-59.0M (prior $50-63M); Advanced Energy $46-52M (prior $43.5-56M).
FDA Safety Communication in March impacted U.S. new customer adoption; 510(k) submissions for dermal/laxity pending.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.